1. Home
  2. AMCX vs EDIT Comparison

AMCX vs EDIT Comparison

Compare AMCX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

SELL

Current Price

$9.11

Market Cap

492.0M

ML Signal

SELL

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$1.90

Market Cap

422.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
EDIT
Founded
1980
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
492.0M
422.3M
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
AMCX
EDIT
Price
$9.11
$1.90
Analyst Decision
Sell
Buy
Analyst Count
8
13
Target Price
★ $9.50
$6.10
AVG Volume (30 Days)
687.2K
★ 2.2M
Earning Date
11-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 132.55
37.50
EPS
N/A
★ N/A
Revenue
★ $2,311,801,000.00
$31,937,000.00
Revenue This Year
$5.04
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 132.64
52 Week Low
$6.47
$1.66
52 Week High
$12.93
$3.94

Technical Indicators

Market Signals
Indicator
AMCX
EDIT
Relative Strength Index (RSI) 46.92 33.51
Support Level $7.34 $1.82
Resistance Level $10.58 $3.00
Average True Range (ATR) 0.49 0.24
MACD 0.23 -0.07
Stochastic Oscillator 69.41 1.35

Price Performance

Historical Comparison
AMCX
EDIT

About AMCX AMC Networks Inc.

AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: